纽约（路透社健康专栏）12月21日电—据《变态反应，哮喘及免疫学年鉴》杂志11月刊一篇报道，舌下减敏疗法（SLIT）治疗成人花粉诱发的呼吸道过敏成效高。
“利用SLIT减少鼻炎的并发症及药物消费，减轻社会经济负担，”意大利Genoa大学Giovanni Passalacqua博士说。“先前已经有强化注射疗法减轻社会负担，但这是首次对实用疗法（SLIT）进行严格评估的结果。”
Passalacqua博士及其同事们对花粉诱发的过敏性鼻炎和哮喘治疗效果进行研究，评估利用SLIT结合标准治疗及单独利用标准治疗的费用及疗效。研究人员报道，SLIT使63.1%的患者症状改善，并预防51.8%的患者出现哮喘，而单独应用标准疗法仅仅使23.2%的患者症状改善，预防28.9%的患者出现哮喘。而且同标准治疗相比，SLIT的直接及间接花费均降低：SLIT患者治疗的总体花费低于国家卫生保健系统预测的4年内单独药物治疗花费，并且低于社会公众预测的2年内单独药物治疗花费。
“SLIT并不能算是强化注射疗法的竞争对手，” Passalacqua博士解释说，“而是将其作为治疗方法的另一选择。它最大的优点在于其最优的安全性和患者的易接受性。”
“SLIT在美国并未正式应用，尽管一些变态反应专家应用它（并且取得了满意的结果），” Passalacqua博士说。“欧洲情况完全不同，SLIT在很多国家中广泛应用（如意大利，德国，法国，西班牙，葡萄牙，希腊及匈牙利）。”当前的问题是SLIT并未得到FDA的批准，“Passalacqua博士补充道。“受到FDA支持的临床研究正在进行中，并有望得到批准。”
Sublingual Immunotherapy Cost-Effective for Pollen-Induced Allergy
By Will Boggs, MD
NEW YORK (Reuters Health) Dec 21 - Sublingual immunotherapy (SLIT) is cost-effective for treating adults with pollen-induced respiratory allergy, according to a report in the November Annals of Allergy, Asthma & Immunology.
"The use of SLIT leads to a socio-economic savings by reducing the comorbidities of rhinitis and drug consumption," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "This fact has been previously envisaged also for injection IT, but this is the first rigorous assessment made by means of a validated economic model."
Dr. Passalacqua and colleagues' study was designed to evaluate the costs and consequences of using SLIT in association with standard treatment compared with standard treatment alone in young adults with pollen-induced allergic rhinitis and asthma.
SLIT improved symptoms of 63.1% of patients and prevented asthma in 51.8% of patients, the authors report, compared with 23.2% and 28.9%, respectively, of patients receiving standard treatment.
Compared with standard treatment, SLIT resulted in lower direct and indirect expenses, the researchers note.
According to the results, the overall cost of treatment for SLIT patients drops below that for patients receiving only drugs at year 4 from the National Healthcare System perspective and at year 2 from the societal perspective.
"SLIT is not to be intended as an antagonist of injection IT," Dr. Passalacqua explained, "rather as an additional therapeutic option. Its best advantage is the optimal safety profile and the good acceptance by the patients."
"SLIT is not officially in use in the USA, although some allergists utilize it (with satisfactory results)," Dr. Passalacqua said. "In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary)."
"The problem is formal, due to the fact that SLIT has not the approval of the FDA," Dr. Passalacqua added. "Clinical studies endorsed by the FDA are currently ongoing to get the approval."
Ann Allergy Asthma Immunol 2006;97:615-621.
http://www.medscape.com/viewarticle/549753
编辑：蓝色幻想
